Amerikanische Gesellschaft für Hirudotherapie

Mucinivorans hirudinis gen. nov., sp. nov., an anaerobic, mucin-degrading bacterium isolated from the digestive tract of the medicinal leech Hirudo verbana

Taxonomy paper published in International Journal of Systematic and Evolutionary Microbiology (2015)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikNelson MC, Bomar L, Maltz M, Graf J · International journal of systematic and evolutionary microbiology, 2015

Abstract

Three anaerobic bacterial strains were isolated from the digestive tract of the medicinal leech Hirudo verbana, using mucin as the primary carbon and energy source. These strains, designated M3(T), M4 and M6, were Gram-stain-negative, non-spore-forming and non-motile. Cells were elongated bacilli approximately 2.4 µm long and 0.6 µm wide. Growth only occurred anaerobically under mesophilic and neutral pH conditions. All three strains could utilize multiple simple and complex sugars as carbon sources, with glucose fermented to acid by-products. The DNA G+C contents of strains M3(T), M4 and M6 were 44.9, 44.8 and 44.8 mol%, respectively. The major cellular fatty acid of strain M3(T) was iso-C15 : 0. Phylogenetic analysis of full-length 16S rRNA gene sequences revealed that the three strains shared >99 % similarity with each other and represent a new lineage within the family Rikenellaceae of the order Bacteroidales, phylum Bacteroidetes. The most closely related bacteria to strain M3(T) based on 16S rRNA gene sequences were Rikenella microfusus DSM 15922(T) (87.3 % similarity) and Alistipes finegoldii AHN 2437(T) (87.4 %). On the basis of phenotypic, genotypic and physiological evidence, strains M3(T), M4 and M6 are proposed as representing a novel species of a new genus within the family Rikenellaceae, for which the name Mucinivorans hirudinis gen. nov., sp. nov. is proposed. The type strain of Mucinivorans hirudinis is M3(T) ( = ATCC BAA-2553(T) = DSM 27344(T)).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, Non-P.H.S.
Indexed MeSH termsAnimalsBacterial Typing TechniquesBacteroidetesBase CompositionDNA, BacterialFatty AcidsGastrointestinal TractHirudo medicinalisMolecular Sequence DataPhylogenyRNA, Ribosomal, 16SSequence Analysis, DNA

Zusammenfassung

Description of Mucinivorans hirudinis gen. nov., sp. nov., the first cultured representative of the previously known Rikenella-like dominant symbiont of the medicinal leech crop, marking a major advance after 20+ years of culture attempts.

Warum dies für die Hirudotherapie relevant ist

This study describes the isolation and taxonomic characterization of three anaerobic, mucin-degrading bacterial strains (M3(T), M4, M6) from the digestive tract of the medicinal leech Hirudo verbana. Based on phenotypic, genotypic, and physiological evidence—including 16S rRNA gene sequencing, DNA G+C content (~44.9 mol%), and fatty acid analysis—the authors propose these strains as a novel species and genus, Mucinivorans hirudinis gen. nov., sp. nov., within the family Rikenellaceae (phylum Bacteroidetes). This work is indirectly relevant to the leech research domain, as characterizing the leech gut microbiota contributes to understanding the microbial ecology of medicinal leeches and may inform future studies on symbiont-host relationships or infection risk. However, this is purely a taxonomy and physiology paper with no clinical, therapeutic, or direct hirudotherapy data, and no pathogenicity or antibiotic resistance findings are reported.

Zitation

Mucinivorans hirudinis gen. nov., sp. nov., an anaerobic, mucin-degrading bacterium isolated from the digestive tract of the medicinal leech Hirudo verbana.

Nelson MC, Bomar L, Maltz M, Graf J · International journal of systematic and evolutionary microbiology, 2015

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.